The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells

BACKGROUND: The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. Due to the probable long lasting treatment with tyrosine-kinase inhibitors (TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Borriello, Adriana, Caldarelli, Ilaria, Basile, Maria Assunta, Bencivenga, Debora, Tramontano, Annunziata, Perrotta, Silverio, Ragione, Fulvio Della, Oliva, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229607/
https://www.ncbi.nlm.nih.gov/pubmed/22164306
http://dx.doi.org/10.1371/journal.pone.0028555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229607/
https://www.ncbi.nlm.nih.gov/pubmed/22164306
http://dx.doi.org/10.1371/journal.pone.0028555

Ejemplares similares